CompletedPhase 4

Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study

46 participantsStarted 2015-01-01

Plain-language summary

This single-arm, retrospective study aims to evaluate the safety and efficacy of subcutaneous treprostinil as a bridge therapy for lung transplantation in patients with severe pulmonary hypertension (PH). A total of 46 patients with either pulmonary arterial hypertension (PAH) or chronic lung disease-associated PH (CLD-PH) were included, all of whom were referred for lung transplantation between January 1, 2015, and September 1, 2024. The study examines changes in clinical, functional, and hemodynamic parameters following 3-6 months of treprostinil therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with severe pulmonary hypertension (PAH or CLD-PH) requiring lung transplantation * Age 18 years or older * Able to provide informed consent Exclusion Criteria: * Patients with PH caused by left heart disease * Patients unable to undergo lung transplantation due to medical conditions * Patients with a history of severe drug allergies

What they're measuring

Change in NYHA Functional Class

Timeframe: Baseline to 3-6 months after treatment initiation

Improvement in 6-Minute Walk Distance (6-MWD)

Timeframe: Baseline to 3-6 months after treatment initiation

Trial details

NCT IDNCT06605326

SponsorGuangzhou Institute of Respiratory Disease

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-01

View on ClinicalTrials.gov More Pulmonary Hypertension trials